Radiation therapy and concurrent @entity900 in management of locoregionally advanced XXXX .

@entity1 @entity137 @entity5 @entity900 @entity189 @entity177
Radiation therapy in combination with chemotherapy in the management of locoregionally advanced @entity189 is evaluated in an attempt to improve locoregional response, reduce locoregional failure and reduce @entity177 . The current study was designed to investigate radiation therapy and concurrent @entity900 in this context. From 1992 through 1997, 70 @entity1 with locoregionally advanced @entity189 were treated with radiation therapy and concurrent @entity900 . External beam radiation dose was 60 Gy for T1, T2 and T3 @entity5 , 70 Gy for T4 @entity5 and 70 Gy for metastatic cervical lymph nodes. An intracavitary brachytherapy boost (10 Gy) was applied for T1, T2 and T3 @entity5 . @entity900 (30 mg/m2) was administered weekly during external beam radiation therapy. Locoregional complete response was achieved in 63 @entity1 , locoregional failure was observed in 4 @entity1 and @entity177 was observed in 15. N-stage predicted @entity177 . Overall survival, locoregional failure-free survival and @entity177 -free survival were 63%, 79% and 75%, respectively, at three years. Grade 3 acute @entity137 was observed in 2 @entity1 , Grade 3 acute mucous membrane @entity137 was observed in 6 and Grade 3 acute hematological @entity137 was observed in 2 @entity1 . Despite improved locoregional response, reduced locoregional failure and improved survival with radiation therapy and concurrent @entity900 , @entity177 remains prevalent for locoregionally advanced @entity189 .
